- Home
- NXGL vs COCP Comparison
NXGL vs COCP Comparison
Compare NXGL & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXGL | COCP |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 15.3M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NXGL | COCP |
|---|---|---|
| Price | $1.23 | $0.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 35.5K | ★ 92.6K |
| Earning Date | 11-11-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,666,000.00 | N/A |
| Revenue This Year | $39.28 | N/A |
| Revenue Next Year | $42.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 73.37 | N/A |
| 52 Week Low | $1.34 | $0.90 |
| 52 Week High | $3.80 | $2.67 |
Technical Indicators
Market Signals| Indicator | NXGL | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 29.84 | 37.45 |
| Support Level | $1.58 | $0.97 |
| Resistance Level | $1.74 | $1.06 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 6.49 | 4.50 |
Price Performance
Historical ComparisonAbout NXGL NexGel Inc
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating and cross-linking technologies.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).